ASX · IMR.AX
Imricor Medical Systems, Inc.
A$1.35+A$0.05 (+3.85%)
Imricor Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
Loading market information…
ASX · IMM.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Immutep Limited’s quoted price sits in the lower half of its reported 52-week range, 95.11% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Immutep Limited’s next earnings report is currently expected on Feb 25, 2027, with estimated earnings per share of -A$0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Immutep Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Feb 27, 2024 | -A$0.02+10.49% vs estimate | A$4.11M+49.47% vs estimate |
|---|
| Q4 2023 | Oct 31, 2023 | -A$0.02+0.05% vs estimate | A$1.91M-77.15% vs estimate |
|---|
| Q2 2023 | Feb 24, 2023 | -A$0.02-24.23% vs estimate | A$2.58M |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$1.35+A$0.05 (+3.85%)
Imricor Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
A$2.77+A$0.04 (+1.47%)
Artrya Limited’s quoted price sits in the lower half of its reported 52-week range, 57.32% below the high.
A$7.22-A$0.11 (-1.5%)
Clinuvel Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 46.44% below the high.
A$1.55-A$0.01 (-0.32%)
Race Oncology Limited’s quoted price sits in the lower half of its reported 52-week range, 59.23% below the high.
A$2.54+A$0.04 (+1.6%)
Mayne Pharma Group Limited’s quoted price sits in the lower half of its reported 52-week range, 59.29% below the high.
A$0.55+A$0.02 (+2.8%)
Orthocell Limited’s quoted price sits in the lower half of its reported 52-week range, 56.18% below the high.
A$0.21-A$0.01 (-2.33%)
Dimerix Limited’s quoted price sits in the lower half of its reported 52-week range, 68.42% below the high.
A$0.13+A$0.01 (+8.33%)
EBR Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.6% below the high.
